Bioventus
BVS
144 hedge funds and large institutions have $448M invested in Bioventus in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 55 increasing their positions, 48 reducing their positions, and 23 closing their positions.
126% more call options, than puts
Call options by funds: $823K | Put options by funds: $364K
15% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 48
1.68% more ownership
Funds ownership: 69.62% → 71.31% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less funds holding
Funds holding: 151 → 144 (-7)
6% less capital invested
Capital invested by funds: $478M → $448M (-$29.6M)
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
+$16.9M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$3.25M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$2.49M |
| 4 |
Renaissance Technologies
New York
|
+$1.65M |
| 5 |
RA
Royce & Associates
New York
|
+$1.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Ophir Asset Management
Sydney,
Australia
|
-$4.46M |
| 2 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
-$3.03M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.68M |
| 4 |
SSIM
Sheets Smith Investment Management
Houston,
Texas
|
-$1.5M |
| 5 |
Morgan Stanley
New York
|
-$1.49M |
BVS Hedge Fund Activity: Q1 2025 in Review
144 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q1 2025, worth a combined $448M — down 6.2% from $478M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of BVS and 16 opened new positions — a net loss of 7 holders — while 48 trimmed existing stakes and 55 added.
The largest buyer was Divisadero Street Capital Management, opening a new position worth an estimated $16.9M. The largest seller was Ophir Asset Management, exiting entirely with an estimated $4.46M sold.
- 144 institutional investors held Bioventus (BVS) as of Q1 2025, down from 151 in Q4 2024.
- Funds reported $448M of Bioventus stock for Q1 2025, down 6.2% quarter-over-quarter.
- 16 funds opened new Bioventus positions in Q1 2025 and 23 closed out, a net change of -7 holders.
- The largest Bioventus buyer in Q1 2025 was Divisadero Street Capital Management, an estimated $16.9M added.
- The largest Bioventus seller in Q1 2025 was Ophir Asset Management, an estimated $4.46M sold.
Based on aggregated 13F filings for Q1 2025.